BDX
$241.82
Becton Dickinson
$1.80
.75%
BDX
Earnings Whisper ®
$3.80
4th Quarter September 2024
Consensus:  $3.77
Revenue:  $5.36 Bil
Thursday
Nov 7
6:30 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch
Latest EPS
Thursday, August 1, 2024

What do you expect when BDX reports earnings?
Beat
Meet
Miss

Where is BDX's stock price going from here?
Up
Flat
Down
Stock chart of BDX
Analysts
Summary of analysts' recommendations for BDX
Score
Grade
Pivots
Resistance
$248.81
$246.65
$244.24

$242.08

Support
$239.67
$237.51
$235.10
Tweet
Growth
Description
Becton, Dickinson and Company, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. BD's operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. The company's organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional. BD Medical: BD Medical's major product lines include needles, syringes and intravenous catheters for medication delivery and generic prefilled injectables. BD Life Sciences - BD Diagnostics provides products for the safe collection and transport of diagnostics specimens to detect a broad range of infectious diseases, healthcare-associated infections and cancer. BD Biosciences produces research and clinical tools that facilitate the study of cells to gain a better understanding of normal and disease processes. With the acquisition of C.R. Bard, BD added a new segment - BD Interventional.
Peers
Boston ScientificStrykerAbbottWaters3MBaxter InternationalTeleflexResMedIntegra LifeSciences HoldingsMerit Medical Systems